CLL
MCID: CHR418
MIFTS: 50

Chronic Leukemia (CLL)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Chronic Leukemia

MalaCards integrated aliases for Chronic Leukemia:

Name: Chronic Leukemia 12 54 15 71
Adult Chronic Leukemia 12
Cll 12
Cml 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1036
NCIt 49 C3483
UMLS 71 C1279296

Summaries for Chronic Leukemia

Disease Ontology : 12 A leukemia that develops slowly.

MalaCards based summary : Chronic Leukemia, also known as adult chronic leukemia, is related to leukemia and chronic neutrophilic leukemia. An important gene associated with Chronic Leukemia is STAT5A (Signal Transducer And Activator Of Transcription 5A), and among its related pathways/superpathways are Akt Signaling and Focal Adhesion. The drugs Chlorambucil and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Chronic leukemia is an increase of abnormal white blood cells. It differs from acute leukemia, and is... more...

Related Diseases for Chronic Leukemia

Diseases in the Leukemia family:

Chronic Leukemia Acute Leukemia
Subacute Leukemia

Diseases related to Chronic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 339)
# Related Disease Score Top Affiliating Genes
1 leukemia 32.6 WT1 U2AF1 STAT3 CCND1 BCR ASXL1
2 chronic neutrophilic leukemia 32.5 U2AF1 TET2 LUC7L2 ASXL1
3 leukemia, chronic lymphocytic 31.9 XIAP U2AF1 STAT5B STAT5A STAT3 PTEN
4 chronic eosinophilic leukemia 31.7 WT1 U2AF1 TET2 STAT5B FIP1L1 ASXL1
5 juvenile myelomonocytic leukemia 31.6 U2AF1 TET2 STAT5A STAT3 PTEN LUC7L2
6 leukemia, chronic myeloid 31.5 WT1 U2AF1 STAT5B STAT5A STAT3 PTEN
7 t-cell leukemia 30.7 XIAP STAT5B STAT5A PTEN CCND1
8 lymphoma, non-hodgkin, familial 30.6 XIAP U2AF1 STAT3 PTEN H2AC18 CCND1
9 burkitt lymphoma 30.5 XIAP STAT3 DIABLO CCND1 BCR
10 myeloid leukemia 30.5 WT1 U2AF1 TET2 STAT5B STAT5A STAT3
11 polycythemia 30.3 TET2 STAT5B STAT5A STAT3 ASXL1
12 neuroblastoma 30.3 XIAP STAT3 RARS1 PTEN DIABLO CCND1
13 acute t cell leukemia 30.2 U2AF1 STAT5B PTEN
14 leukemia, acute lymphoblastic 30.2 XIAP WT1 U2AF1 STAT5B PRAME H2AC18
15 peripheral t-cell lymphoma 30.2 TET2 STAT3 PTEN CCND1
16 indolent systemic mastocytosis 30.0 U2AF1 TET2 FIP1L1 ASXL1
17 systemic mastocytosis 29.9 TET2 STAT5B STAT5A FIP1L1 ASXL1
18 mastocytosis 29.9 TET2 STAT5B STAT5A FIP1L1 ASXL1
19 polycythemia vera 29.9 TET2 STAT5B STAT5A STAT3 FIP1L1 ASXL1
20 atypical chronic myeloid leukemia 29.8 U2AF1 TET2 RARS1 LUC7L2 ASXL1
21 myelofibrosis 29.7 WT1 U2AF1 TET2 STAT5B STAT5A STAT3
22 myelodysplastic syndrome 29.5 XIAP WT1 U2AF1 TET2 STAT5B STAT5A
23 myeloma, multiple 29.3 XIAP U2AF1 STAT5B STAT5A STAT3 PTEN
24 acute promyelocytic leukemia 29.3 XIAP WT1 STAT5B STAT5A STAT3 RARS1
25 hematologic cancer 29.2 XIAP WT1 U2AF1 STAT5B STAT5A STAT3
26 aplastic anemia 29.2 WT1 U2AF1 TET2 STAT3 H2AC18 GFI1B
27 myeloproliferative neoplasm 29.2 WT1 U2AF1 TET2 STAT5B STAT5A STAT3
28 essential thrombocythemia 29.2 U2AF1 TET2 STAT5B STAT5A STAT3 CCND1
29 leukemia, acute myeloid 28.4 XIAP WT1 U2AF1 TET2 STAT5B STAT5A
30 cll/sll 12.4
31 chronic myelomonocytic leukemia 12.0
32 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.2
33 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.2
34 subacute leukemia 11.1
35 childhood leukemia 11.1
36 glioblastoma neural subtype 10.6 STAT5B STAT5A
37 large granular lymphocyte leukemia 10.6 STAT5B STAT3
38 microcystic stromal tumor 10.6 WT1 CCND1
39 b-cell lymphoma 10.6
40 mixed lacrimal gland cancer 10.6 STAT3 CCND1
41 jak3-deficient severe combined immunodeficiency 10.5 STAT5B STAT5A
42 skin papilloma 10.5 STAT3 PTEN CCND1
43 systemic mastocytosis with associated hematologic neoplasm 10.5 TET2 ASXL1
44 rhabdoid cancer 10.5 WT1 H2AC18 CCND1
45 lymphoma, hodgkin, classic 10.5
46 thrombocytopenia 10.5
47 mixed cell type cancer 10.5 WT1 PTEN H2AC18
48 lymphocytic leukemia 10.5
49 respiratory system benign neoplasm 10.4 PTEN H2AC18 CCND1
50 diffuse large b-cell lymphoma 10.4

Comorbidity relations with Chronic Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Chronic Leukemia:



Diseases related to Chronic Leukemia

Symptoms & Phenotypes for Chronic Leukemia

GenomeRNAi Phenotypes related to Chronic Leukemia according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.97 STAT5B WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.97 RARS1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.97 STAT5B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.97 WT1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.97 STAT5B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.97 STAT5B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.97 RARS1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.97 LUC7L2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.97 PTEN
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.97 PTEN WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.97 RARS1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.97 PTEN
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.97 LUC7L2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.97 FIP1L1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.97 PTEN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.97 RARS1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.97 STAT5B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.97 LUC7L2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.97 RARS1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.97 FIP1L1 LUC7L2 PTEN RARS1 STAT5B WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.97 WT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.97 STAT5B
23 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.97 WT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.97 WT1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.97 PTEN
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.97 WT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.97 STAT5B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.97 WT1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.97 STAT5B
30 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.97 LUC7L2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.97 FIP1L1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.97 LUC7L2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.97 PTEN
34 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.97 FIP1L1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.97 FIP1L1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.97 WT1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.97 PTEN
38 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 PTEN WT1

MGI Mouse Phenotypes related to Chronic Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 ASXL1 BCR CCND1 DIABLO GFI1B HGF
2 growth/size/body region MP:0005378 10.18 ASXL1 BCR CCND1 DIABLO HGF PTEN
3 hematopoietic system MP:0005397 10.18 ASXL1 BCR CCND1 GFI1B HGF PTEN
4 endocrine/exocrine gland MP:0005379 10.13 ASXL1 CCND1 PTEN SOAT1 STAT3 STAT5A
5 immune system MP:0005387 10.1 ASXL1 BCR CCND1 GFI1B PTEN SOAT1
6 integument MP:0010771 9.91 CCND1 GFI1B PTEN RARS1 SOAT1 STAT3
7 liver/biliary system MP:0005370 9.85 ASXL1 BCR HGF PTEN SOAT1 STAT3
8 neoplasm MP:0002006 9.5 ASXL1 CCND1 PTEN SOAT1 STAT3 TET2
9 normal MP:0002873 9.32 BCR CCND1 DIABLO PTEN STAT3 STAT5A

Drugs & Therapeutics for Chronic Leukemia

Drugs for Chronic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 254)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorambucil Approved Phase 3 305-03-3 2708
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
4
Daunorubicin Approved Phase 3 20830-81-3 30323
5
Idarubicin Approved Phase 3 58957-92-9 42890
6
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
9
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
10
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
11
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
12
Thioguanine Approved Phase 3 154-42-7 2723601
13
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
14
Lorazepam Approved Phase 3 846-49-1 3958
15
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
16
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
17
Lenalidomide Approved Phase 3 191732-72-6 216326
18
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
19
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
20
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
21
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
22
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
23
leucovorin Approved Phase 3 58-05-9 6006 143
24
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
26
Lonafarnib Investigational Phase 3 193275-84-2 148195
27 Anti-Inflammatory Agents Phase 3
28 Analgesics, Non-Narcotic Phase 3
29 Analgesics Phase 3
30 Antiemetics Phase 2, Phase 3
31 Gastrointestinal Agents Phase 3
32 Neuroprotective Agents Phase 2, Phase 3
33 Hormone Antagonists Phase 3
34 Autonomic Agents Phase 2, Phase 3
35 glucocorticoids Phase 3
36 Hormones Phase 3
37 Anti-Bacterial Agents Phase 3
38 Antibiotics, Antitubercular Phase 3
39 Topoisomerase Inhibitors Phase 3
40 Interleukin-2 Phase 3
41 Anti-Retroviral Agents Phase 3
42 Anti-HIV Agents Phase 3
43 Vidarabine Phosphate Phase 3
44 Etoposide phosphate Phase 3
45 BB 1101 Phase 3
46 Hydrocortisone hemisuccinate Phase 3
47 Hydrocortisone 17-butyrate 21-propionate Phase 3
48 Hydrocortisone-17-butyrate Phase 3
49
asparaginase Phase 3
50 N-Methylaspartate Phase 3

Interventional clinical trials:

(show top 50) (show all 231)
# Name Status NCT ID Phase Drugs
1 The Effect of Special Diets on Weight and Nutritional Intake in Haematological Cancer Patients Completed NCT02880709 Phase 4
2 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
3 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
4 A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT00471497 Phase 3 nilotinib;imatinib
5 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
6 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
7 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
8 A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination With Venetoclax With and Without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia Without Del(17p) or TP53 Mutation Recruiting NCT03836261 Phase 3 Acalabrutinib;Venetoclax;Chemoimmunotherapy;Obinutuzumab
9 The Clinical Efficacy of Azacytidine Combined With HAG Regimen in Elderly Patients With Myeloid Malignancy Recruiting NCT03873311 Phase 3 Azacytidine, HAG Regimen
10 A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) Recruiting NCT03306264 Phase 3 ASTX727;Dacogen
11 A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
12 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Recruiting NCT00619879 Phase 3 Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients;Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
13 Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
14 Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
15 Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
16 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Active, not recruiting NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
17 A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia Terminated NCT00109538 Phase 3 Lonafarnib
18 Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
19 A Phase III Randomized, Open- Label Multi-center Study of Nilotinib Versus Imatinib in Adult Patients With Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Cytogenetic Response (CyR) on Imatinib Terminated NCT00519090 Phase 3 Imatinib;Nilotinib (AMN107)
20 Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure Unknown status NCT01133886 Phase 2 Decitabine
21 A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Unknown status NCT01368757 Phase 1, Phase 2 Revlimid
22 A Phase I/II, Open-Label, Multicenter Study of the Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML) Unknown status NCT03040401 Phase 1, Phase 2 Cohort 1, Ceplene® and Proleukin®;Cohort 2, Ceplene® and Proleukin®;Cohort 3, Ceplene® and Proleukin®
23 Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Unknown status NCT02190695 Phase 2 Decitabine;Carboplatin;Arsenic trioxide
24 A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk MDS and AML With Del 5q Unknown status NCT00885508 Phase 2 Lenalidomide
25 Dasatinib Combination for Chronic Lymphocytic Leukemia Patients With Chemo Refractory Disease Unknown status NCT01051115 Phase 2 Dasatinib
26 A Pilot Trial of OSI-461 in Patients With Chronic Lymphocytic Leukemia Completed NCT00073489 Phase 2 OSI-461
27 A Phase II Study of Decitabine in Patients With Chronic Myelomonocytic Leukemia Completed NCT01098084 Phase 2 Decitabine
28 A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia Completed NCT00136409 Phase 2 Imatinib mesylate
29 A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies Completed NCT00719836 Phase 1, Phase 2 SB1518
30 A Phase II Multicenter Open-label Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia Completed NCT01251627 Phase 2 Decitabine
31 A Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known as STI-571) In Patients With Myelofibrosis Completed NCT00039416 Phase 2 imatinib mesylate
32 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2 imatinib mesylate
33 A Phase II Study of Sunitinib Malate (Sutent®; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Completed NCT00451048 Phase 2 sunitinib malate
34 Treatment of Post-Transplant Relapse and Persistent Disease in Patients With MDS, CMML and AML With Azacitidine Completed NCT01083706 Phase 2 azacitidine
35 A Pilot Phase II Study of Erlotinib for the Treatment of Patients With Refractory/Relapsed AML Completed NCT01664897 Phase 2 Erlotinib Hydrochloride
36 An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Completed NCT01736683 Phase 2 Sotatercept
37 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
38 Phase II Study of Thalidomide in the Treatment of Myelodysplastic Syndromes in Adults: A Clinical and Biologic Study Completed NCT00015990 Phase 2 thalidomide
39 A Phase II Study Of CCI-779 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Or Chronic Myeloid Leukemia In Blastic-Phase Completed NCT00084916 Phase 2 temsirolimus
40 Phase II Trial of Liposomal Daunorubicin (Daunoxome) and SU5416 (NSC 696819) in Patients With AML, RAEB, RAEB-T or CMML in Transformation Refractory to One Course of Induction Chemotherapy Completed NCT00005942 Phase 1, Phase 2 liposomal daunorubicin citrate;semaxanib
41 Phase I/II Study of Tipifarnib [Zarnestra, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders Completed NCT02210858 Phase 1, Phase 2 Tipifarnib
42 A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia (CMML) Completed NCT01350947 Phase 2 5-Azacitidine
43 Clinical and Biological Evaluation of Azacitidine in Transfusion-dependent Patients With Low and Intermediate-1 Risk MDS, and Low-risk CMML, Who Are Either Refractory to or Not Eligible for Treatment With Erythropoietin +/- G-CSF Completed NCT01048034 Phase 2 Azacitidine;Erythropoetin
44 A Proof of Concept Study of Non-DNA Damaging DNMT1 Depletion Therapy for Myelodysplastic Syndrome Completed NCT01165996 Phase 1, Phase 2 decitabine
45 A Phase 2 Study of Azacitidine in Chronic Myelomonocytic Leukemia (CMML) Completed NCT01235117 Phase 2 azacitidine
46 A Phase II Study of Ofatumumab in Combination With High-dose Methylprednisolone in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Completed NCT01191190 Phase 2 Ofatumumab/HDMP
47 Phase I/II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant Completed NCT00052520 Phase 1, Phase 2
48 A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response Completed NCT02197676 Phase 2 SGI-110 administration
49 Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Less Than Age 65 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm Completed NCT01101880 Phase 2 clofarabine;cytarabine
50 Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC) Completed NCT00381550 Phase 2 fludarabine phosphate;triapine

Search NIH Clinical Center for Chronic Leukemia

Genetic Tests for Chronic Leukemia

Anatomical Context for Chronic Leukemia

MalaCards organs/tissues related to Chronic Leukemia:

40
Myeloid, Bone, T Cells, Bone Marrow, B Cells, Liver, Lung

Publications for Chronic Leukemia

Articles related to Chronic Leukemia:

(show top 50) (show all 806)
# Title Authors PMID Year
1
[Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131]. 54 61
20352702 2010
2
Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. 54 61
9150348 1997
3
Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. 54 61
7911548 1994
4
Differences between blastic chronic myeloid leukemia and Ph-positive acute leukemia. 54 61
8251902 1993
5
Cytogenetic and molecular changes in leukemia found among atomic bomb survivors. 54 61
1762103 1991
6
Associations between genetic polymorphisms in interleukin-10 and hematological oncology: evidence from a meta-analysis. 61
31910710 2020
7
Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. 61
31688455 2020
8
A sudden bilateral hearing loss caused by inner ear hemorrhage. 61
31178427 2020
9
Chemoenzymatic Synthesis of Enantiomeric, Bicyclic δ-Halo-γ-lactones with a Cyclohexane Ring, Their Biological Activity and Interaction with Biological Membranes. 61
31935977 2020
10
Targeted blocking of miR328 lysosomal degradation with alkalized exosomes sensitizes the chronic leukemia cells to imatinib. 61
31701195 2019
11
Sensor array based on single carbon quantum dot for fluorometric differentiation of all natural amino acids. 61
31784824 2019
12
MicroRNA in leukemia: Tumor suppressors and oncogenes with prognostic potential. 61
30515779 2019
13
Signaling pathways involved in chronic myeloid leukemia pathogenesis: The importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells. 61
31231484 2019
14
Effects of GST null genotypes on individual susceptibility to leukemia: A meta-analysis. 61
30659796 2019
15
THE FORECAST OF LETHAL OUTCOME IN CHRONIC LEUKEMIA PATIENTS WITH PNEUMONIA. 61
31101784 2019
16
Disparities in place of death for patients with hematological malignancies, 1999 to 2015. 61
30709864 2019
17
Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. 61
30093158 2019
18
Potential Leukemic Cells Engraftment After Hematopoietic Stem Cell Transplantation From Unrelated Donors With Undiagnosed Chronic Leukemia. 61
30509616 2018
19
Effects of GST variants on the risk odds of hematological malignancy: A meta-analysis. 61
30537151 2018
20
Extranodal Richter's syndrome of the urinary bladder. 61
30337788 2018
21
Safety and Outcome of Percutaneous Drainage of Pericardial Effusions in Patients with Cancer. 61
30064854 2018
22
Pemphigus and hematologic malignancies: A population-based study of 11,859 patients. 61
29198780 2018
23
Genetic Variation of Costimulatory Molecules, Including Cytotoxic T-Lymphocyte Antigen 4, Inducible T-Cell Costimulator, Cluster Differentiation 28, and Programmed Cell Death 1 Genes, in Iranian Patients With Leukemia. 61
29697355 2018
24
Expression of aberrant antigens in hematological malignancies: A single center experience. 61
29805426 2018
25
MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death. 61
29493383 2018
26
Targeted drug delivery for tumor therapy inside the bone marrow. 61
29182960 2018
27
Ocular Manifestations in Leukemias and Their Correlation with Hematologic Parameters at a Tertiary Care Setting in South India. 61
31047297 2018
28
Therapeutic targeting of CK2 in acute and chronic leukemias. 61
28951560 2018
29
[Molecular markers of the oral mucosa damage in patients with leukemia.] 61
30702225 2018
30
Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans. 61
28654153 2017
31
Purification of polysaccharide from artificially cultivated Anoectochilus roxburghii (wall.) Lindl. by high-speed counter current chromatography and its antitumor activity. 61
28892307 2017
32
[Clinical Application Value of Peripheral Blood Diagnostic Report]. 61
29061005 2017
33
GTF2I Mutations Are Common in Thymic Epithelial Tumors But Not in Hematological Malignancies. 61
28982856 2017
34
Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017! 61
28546462 2017
35
Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. 61
28174232 2017
36
Indwelling Pleural Catheters for Patients with Hematologic Malignancies. A 14-Year, Single-Center Experience. 61
28326798 2017
37
Pulmonary Manifestations of Lymphoma and Leukemia. 61
28477632 2017
38
Atypical chronic myeloid leukemia in a German Shepherd Dog. 61
28205462 2017
39
Differential Expression of Circadian Genes in Leukemia and a Possible Role for Sirt1 in Restoring the Circadian Clock in Chronic Myeloid Leukemia. 61
30210557 2017
40
Correlation of Cadmium and Magnesium in the Blood and Serum Samples of Smokers and Non-Smokers Chronic Leukemia Patients. 61
27511371 2017
41
Higher dose of CD34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients. 61
27888540 2017
42
Noninvasive Ventilation in Patients With Hematologic Malignancy. 61
28142306 2017
43
Leukocytosis and Leukemia. 61
27866578 2016
44
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. 61
27579615 2016
45
Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. 61
27229716 2016
46
A Systematic Review of Psychometric Properties of Health-Related Quality-of-Life and Symptom Instruments in Adult Acute Leukemia Survivors. 61
26645111 2016
47
Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer. 61
27400009 2016
48
Your patient has chronic leukemia: Now what? 61
27505878 2016
49
Ocular manifestations in leukemia and myeloproliferative disorders and their association with hematological parameters. 61
27549412 2016
50
Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells. 61
27055869 2016

Variations for Chronic Leukemia

Expression for Chronic Leukemia

Search GEO for disease gene expression data for Chronic Leukemia.

Pathways for Chronic Leukemia

Pathways related to Chronic Leukemia according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 XIAP STAT5B STAT5A STAT3 PTEN HGF
2
Show member pathways
12.84 XIAP STAT3 PTEN HGF CCND1
3
Show member pathways
12.8 STAT5B STAT5A STAT3 PTEN CCND1 BCR
4
Show member pathways
12.73 STAT5B STAT5A STAT3 PTEN CCND1
5 12.52 STAT5B STAT5A STAT3 PRAME GFI1B
6
Show member pathways
12.51 STAT5B STAT5A STAT3 PTEN HGF CCND1
7
Show member pathways
12.44 STAT5B STAT5A STAT3 PTEN HGF CCND1
8
Show member pathways
12.42 STAT5B STAT5A STAT3 PTEN CCND1
9
Show member pathways
12.31 STAT5B STAT5A STAT3 CCND1
10
Show member pathways
12.29 STAT5B STAT5A STAT3 PTEN CCND1
11 12.28 XIAP STAT5B STAT5A STAT3 PTEN HGF
12 12.25 STAT5B STAT5A STAT3 CCND1
13 12.2 XIAP STAT5B STAT5A PTEN CCND1
14 12.15 STAT5B STAT5A STAT3 PTEN
15
Show member pathways
12.14 STAT5B STAT5A STAT3 PTEN
16
Show member pathways
12.12 STAT5B STAT5A STAT3 BCR
17
Show member pathways
12 XIAP STAT5B STAT5A STAT3 H2AC18
18 11.83 STAT5B STAT5A STAT3 CCND1
19 11.83 STAT5B STAT5A STAT3 CCND1
20 11.81 XIAP PTEN CCND1
21 11.8 STAT3 PTEN CCND1
22
Show member pathways
11.78 XIAP STAT5B STAT5A STAT3
23
Show member pathways
11.73 STAT5B STAT5A STAT3 BCR
24 11.72 STAT5B STAT5A STAT3
25 11.65 STAT5B STAT5A STAT3
26 11.56 XIAP PTEN CCND1
27 11.51 STAT5B STAT5A STAT3
28 11.47 STAT5B STAT5A STAT3
29
Show member pathways
11.4 STAT5B STAT5A STAT3
30 11.38 STAT5B STAT5A STAT3
31
Show member pathways
11.36 STAT5B STAT5A STAT3
32 11.36 STAT5B STAT5A STAT3 PTEN
33 11.34 STAT5B STAT5A STAT3
34
Show member pathways
11.22 STAT5B STAT5A STAT3 CCND1
35
Show member pathways
11.19 STAT5B STAT5A STAT3
36 11.16 STAT5B STAT5A HGF
37
Show member pathways
11.08 STAT5B STAT5A STAT3 HGF
38 10.2 STAT5B STAT5A STAT3 CCND1

GO Terms for Chronic Leukemia

Cellular components related to Chronic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.86 XIAP WT1 U2AF1 TET2 STAT5B STAT5A
2 nucleoplasm GO:0005654 9.47 XIAP WT1 U2AF1 STAT5B STAT5A STAT3

Biological processes related to Chronic Leukemia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 WT1 TET2 STAT5B STAT5A STAT3 HGF
2 cytokine-mediated signaling pathway GO:0019221 9.88 STAT5B STAT5A STAT3 HGF CCND1
3 regulation of cell proliferation GO:0042127 9.86 XIAP STAT5B STAT5A STAT3
4 regulation of cell cycle GO:0051726 9.8 STAT3 PTEN CCND1 BCR
5 response to organic substance GO:0010033 9.77 STAT3 PTEN CCND1
6 response to organic cyclic compound GO:0014070 9.76 TET2 STAT3 PTEN CCND1
7 response to peptide hormone GO:0043434 9.71 STAT5B STAT5A STAT3
8 lactation GO:0007595 9.69 STAT5B STAT5A CCND1
9 response to estradiol GO:0032355 9.67 STAT5B STAT3 PTEN CCND1
10 interleukin-7-mediated signaling pathway GO:0038111 9.61 STAT5B STAT5A STAT3
11 interleukin-2-mediated signaling pathway GO:0038110 9.58 STAT5B STAT5A
12 response to leptin GO:0044321 9.58 STAT3 CCND1
13 JAK-STAT cascade GO:0007259 9.58 STAT5B STAT5A STAT3
14 cellular response to leptin stimulus GO:0044320 9.57 STAT3 PTEN
15 taurine metabolic process GO:0019530 9.52 STAT5B STAT5A
16 regulation of multicellular organism growth GO:0040014 9.5 STAT5B STAT5A STAT3
17 negative regulation of apoptotic process GO:0043066 9.5 XIAP WT1 STAT5B STAT3 PTEN PRAME
18 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.43 STAT5B STAT5A STAT3
19 interleukin-15-mediated signaling pathway GO:0035723 9.33 STAT5B STAT5A STAT3
20 interleukin-9-mediated signaling pathway GO:0038113 8.8 STAT5B STAT5A STAT3

Molecular functions related to Chronic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 XIAP WT1 U2AF1 TET2 STAT5B STAT5A
2 glucocorticoid receptor binding GO:0035259 8.96 STAT5B STAT3

Sources for Chronic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....